参考文献/References:
[1] Imai E, Nakamura T, Atsuta N, et al. A nerve conduction study predicts the prognosis of sporadic amyotrophic lateral sclerosis[J]. J Neurol, 2020, 267(9): 2524-2532.
[2] Vucic S, Rutkove SB. Neurophysiological biomarkers in amyotrophic lateral sclerosis[J]. Curr Opin Neurol, 2018, 31(5): 640-647.
[3] Huynh W, Dharmadasa T, Vucic S, et al. Functional biomarkers for amyotrophic lateral sclerosis[J]. Front Neurol, 2018, 9: 1141.
[4] Rajagopalan V, Pioro EP. Unbiased MRI analyses identify micropathologic differences between upper motor Neuron-Predominant ALS phenotypes[J]. Front Neurosci, 2019, 13: 704.
[5] Al-Chalabi A, Hardiman O, Kiernan MC, et al. Amyotrophic lateral sclerosis: moving towards a new classification system[J]. Lancet Neurol, 2016, 15(11): 1182-1194.
[6] Vucic S, Kiernan MC. Utility of transcranial magnetic stimulation in delineating amyotrophic lateral sclerosis pathophysiology[J]. Handb Clin Neurol, 2013, 116: 561-575.
[7] Huynh W, Simon NG, Grosskreutz J, et al. Assessment of the upper motor neuron in amyotrophic lateral sclerosis[J]. Clin Neurophysiol, 2016, 127(7): 2643-2660.
[8] Vucic S, Ziemann U, Eisen A, et al. Transcranial magnetic stimulation and amyotrophic lateral sclerosis: pathophysiological insights[J]. J Neurol Neurosurg Psychiatry, 2013, 84(10): 1161-1170.
[9] Chervyakov AV, Bakulin IS, Savitskaya NG, et al. Navigated transcranial magnetic stimulation in amyotrophic lateral sclerosis[J]. Muscle Nerve, 2015, 51(1): 125-131.
[10] Attarian S, Azulay JP, Lardillier D, et al. Transcranial magnetic stimulation in lower motor neuron diseases[J]. Clin Neurophysiol, 2005, 116(1): 35-42.
[11] Menon P, Geevasinga N, Van Den Bos M, et al. Cortical hyperexcitability and disease spread in amyotrophic lateral sclerosis[J]. European Journal of Neurology, 2017, 24(6): 816-824.
[12] Grieve SM, Menon P, Korgaonkar MS, et al. Potential structural and functional biomarkers of upper motor neuron dysfunction in ALS[J]. Amyotroph Lateral Scler Frontotemporal Degener, 2015, 17(1/2): 85-92.
[13] Civardi C, Collini A, Mazzini L, et al. Single-pulse transcranial magnetic stimulation in amyotrophic lateral sclerosis[J]. Muscle Nerve, 2020, 61(3): 330-337.
[14] Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis[J]. Lancet, 2011, 377(9769): 942-955.
[15] Floyd AG, Yu QP, Piboolnurak P, et al. Transcranial magnetic stimulation in ALS: utility of central motor conduction tests[J]. Neurology, 2009, 72(6): 498-504.
[16] Vucic S, Nicholson GA, Kiernan MC. Cortical excitability in hereditary motor neuronopathy with pyramidal signs: comparison with ALS[J]. J Neurol Neurosurg Psychiatry, 2010, 81(1): 97-100.
[17] Vucic S, Howells J, Trevillion L, et al. Assessment of cortical excitability using threshold tracking techniques[J]. Muscle Nerve, 2006, 33(4): 477-486.
[18] Menon P, Kiernan MC, Vucic S. Cortical hyperexcitability precedes lower motor neuron dysfunction in ALS[J]. Clin Neurophysiol, 2015, 126(4): 803-809.
[19] Menon P, Geevasinga N, Yiannikas C, et al. Sensitivity and specificity of threshold tracking transcranial magnetic stimulation for diagnosis of amyotrophic lateral sclerosis: a prospective study[J]. Lancet Neurol, 2015, 14(5): 478-484.
[20] Vucic S, Nicholson GA, Kiernan MC. Cortical hyperexcitability May precede the onset of familial amyotrophic lateral sclerosis[J]. Brain, 2008, 131(Pt 6): 1540-1550.
[21] Geevasinga N, Menon P, Yiannikas C, et al. Diagnostic utility of cortical excitability studies in amyotrophic lateral sclerosis[J]. European Journal of Neurology, 2014, 21(12): 1451-1457.
[22] Shibuya K, Park SB, Geevasinga N, et al. Motor cortical function determines prognosis in sporadic ALS[J]. Neurology, 2016, 87(5): 513-520.
[23] Vucic S, Lin CS, Cheah BC, et al. Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis[J]. Brain, 2013, 136(Pt 5): 1361-1370.
[24] Geevasinga N, Menon P, Ng K, et al. Riluzole exerts transient modulating effects on cortical and axonal hyperexcitability in ALS[J]. Amyotroph Lateral Scler Frontotemporal Degener, 2016, 17(7/8): 580-588.
[25] Escorcio-Bezerra ML, Abrahao A, Nunes KF, et al. Motor unit number index and neurophysiological index as candidate biomarkers of presymptomatic motor neuron loss in amyotrophic lateral sclerosis[J]. Muscle Nerve, 2018, 58(2): 204-212.
[26] Bromberg MB. Electrodiagnostic studies in clinical trials for motor neuron disease[J]. J Clin Neurophysiol, 1998, 15(2): 117-128.
[27] De Carvalho M, Swash M. Nerve conduction studies in amyotrophic lateral sclerosis[J]. Muscle Nerve, 2000, 23(3): 344-352.
[28] Cheah BC, Vucic S, Krishnan AV, et al. Neurophysiological index as a biomarker for ALS progression: validity of mixed effects models[J]. Amyotroph Lateral Scler, 2011, 12(1): 33-38.
[29] Cao B, Wei Q, Ou R, et al. Neurophysiological index is associated with the survival of patients with amyotrophic lateral sclerosis[J]. Clin Neurophysiol, 2019, 130(9): 1730-1733.
[30] Gooch CL, Shefner JM. ALS surrogate markers. MUNE[J]. Amyotroph Lateral Scler Other Motor Neuron Disord, 2004, 5(Suppl 1): 104-107.
[31] Jacobsen AB, Bostock H, Tankisi H. CMAP scan MUNE(MScan)- A novel motor unit number estimation(MUNE)method[J]. J Vis Exp, 2018(136): 56805.
[32] Kristensen RS, Bostock H, Tan SV, et al. MScanFit motor unit number estimation(MScan)and muscle velocity recovery cycle recordings in amyotrophic lateral sclerosis patients[J]. Clin Neurophysiol, 2019, 130(8): 1280-1288.
[33] Jacobsen AB, Bostock H, Tankisi H. Following disease progression in motor neuron disorders with 3 motor unit number estimation methods[J]. Muscle Nerve, 2019, 59(1): 82-87.
[34] Moldovan M, Vucic S. Is motor unit number index(MUNIX)an index of compound muscle action potential amplitude rather than motor unit number?[J]. Clin Neurophysiol, 2019, 130(9): 1686-1687.
[35] Nandedkar SD, Barkhaus PE, St?berg EV. Motor unit number index(MUNIX)and compound muscle action potential amplitude: A reappraisal[J]. Clin Neurophysiol, 2019, 130(10): 2010-2011.
[36] Bostock H, Jacobsen AB, Tankisi H. Motor unit number index and compound muscle action potential amplitude[J]. Clin Neurophysiol, 2019, 130(9): 1734-1740.
[37] Alix J, Mcdonough H, Sonbas B, et al. Multi-dimensional electrical impedance myography of the tongue as a potential biomarker for amyotrophic lateral sclerosis[J]. Clin Neurophysiol, 2020, 131(4): 799-808.
[38] Shefner JM, Rutkove SB, Caress JB, et al. Reducing sample size requirements for future ALS clinical trials with a dedicated electrical impedance myography system[J]. Amyotroph Lateral Scler Frontotemporal Degener, 2018, 19(7/8): 555-561.
[39] Park SB, Kiernan MC, Vucic S. Axonal excitability in amyotrophic lateral sclerosis: axonal excitability in ALS[J]. Neurotherapeutics, 2017, 14(1): 78-90.
[40] Kanai K, Shibuya K, Kuwabara S. [Motor axonal excitability properties are strong predictors for survival in amyotrophic lateral sclerosis][J]. Rinsho Shinkeigaku, 2011, 51(11): 1118-1119.
[41] Weiss MD, Macklin EA, Simmons Z, et al. A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression[J]. Neurology, 2016, 86(16): 1474-1481.
[42] Park SB, Vucic S, Cheah BC, et al. Flecainide in amyotrophic lateral sclerosis as a neuroprotective strategy(FANS): A randomized Placebo-Controlled trial[J]. EBioMedicine, 2015, 2(12): 1916-1922.